Halozyme Therapeutics, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Helen I. Torley
- Full Time Employees
- 423
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 12390 El Camino Real San Diego CA United States of America 92121
- IPO Date
- Mar 16, 2004
- CIK
- 0001159036
- Website
- halozyme.com
- Similar Companies
- Business
- Halozyme Therapeutics, Inc. (NASDAQ: HALO) is a biopharmaceutical company that develops and commercializes proprietary enzyme-based drug delivery technologies and oncology therapies. The company's core ENHANZE platform, powered by the patented recombinant human hyaluronidase enzyme (rHuPH20), facilitates subcutaneous delivery of injectable biologics including monoclonal antibodies, other therapeutic molecules, small molecules, and fluids; it supports partnered products such as DARZALEX FASPRO (subcutaneous), Phesgo, VYVGART Hytrulo, Tecentriq Subcutaneous, and Ocrevus Subcutaneous across oncology, immunology, and neurology indications. Halozyme also commercializes XYosted, a testosterone replacement therapy via an auto-injector, and previously marketed Hylenex and Tlando prior to license terminations. Founded in 1998 and headquartered in San Diego, California, Halozyme operates primarily in the United States with global partnerships enabling international reach through collaborators in pharmaceutical and biotechnology sectors targeting diabetes, cancer, dermatology, autoimmune diseases, and rare disorders. In recent developments, Halozyme completed the acquisition of Elektrofi in late 2025 for up to $900 million, integrating the Hypercon microparticle technology to expand subcutaneous delivery options and strengthen partnerships with big pharma; the deal includes $750 million upfront plus milestones tied to product approvals, with royalties expected from 2030. The company expanded its argenx collaboration with an upfront payment and milestones, secured a new global agreement with Merus N.V. for ENHANZE in bispecific antibodies, and gained regulatory approvals for Roche's Tecentriq and Ocrevus subcutaneous formulations; partners nominated five new targets for clinical advancement in 2024, contributing to record 2024 revenue exceeding $1 billion. These initiatives underscore Halozyme's focus on organic pipeline growth, strategic alliances, and share repurchases up to $250 million.
Halozyme to Report Second Quarter 2026 Financial and Operating Results
Halozyme's Partnerships, Earnings Growth See Shares Near All-Time Highs
HALO Inks Deal With INCY to Support Cancer Therapy Development
Halozyme Announces Global Collaboration and License Agreement with Incyte to Support the Development of Subcutaneous Formulations of INCA033989 Using its ENHANZE® Technology
Fifth Third Bancorp Grows Position in Halozyme Therapeutics, Inc. $HALO
Inflation Cools But US-Iran Tensions Rise: 4 Value Stocks to Buy Now
Time for HALO Sectors & ETFs?
Time to Buy Wide Moat & HALO ETFs?
Halozyme Appoints David Ramsay as President Drug Delivery
Halozyme Confirms It Projects Zero to Minimal Impact to Royalty Revenue Through At Least 2035 Based on Newly Released Draft Medicare Drug Price Negotiation Program Proposed Rule for IPAY 2029
Halozyme Therapeutics (HALO) Up 0.8% Since Last Earnings Report: Can It Continue?
Anti-AI Investing: The HALO Moat Goes Off The Rails
Sky Harbour: The Ultimate HALO Investment Taking Flight
Anti-AI Investing: The HALO Moat
Implied Volatility Surging for Halozyme Therapeutics Stock Options
Halozyme Therapeutics: Royalty King
Nexalin Acquires AI-Integrated Digital Health Platform Behind HALO™ Clarity and Nexalin NeuroCare™ Ahead of Planned FDA Pivotal Trial
One of the market's hottest stock themes is buying everything AI can't replace
Roundhill launches "HALO" ETF
Halozyme's Q1 Earnings & Revenues Beat Estimates, Stock Up